Prestige Consumer Healthc... (PBH)
NYSE: PBH
· Real-Time Price · USD
65.04
-1.71 (-2.56%)
At close: Sep 05, 2025, 3:59 PM
65.26
0.34%
After-hours: Sep 05, 2025, 06:09 PM EDT
Prestige Consumer Healthcare Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Analgesics Revenue | 28.93M | 30.2M | 30.98M | 28.22M | 28.29M | 27.8M | 30.27M | 31.36M | 28.02M | 27.68M | 30.04M | 33.29M | 28.25M | 24.73M | 31.03M | 30.34M | 33.23M | 30.26M | 29.85M | 30.89M | 28.14M | 27.66M | 28.5M | 29.07M | 28.77M | 27.54M | 29.46M | 28.76M | 28.41M | 28.78M | 31.45M | 29.39M | 29.8M | 30.1M | 32.88M | 30.54M | 28.65M | 30.8M | 30.9M | 30.38M | 27.38M | 30.15M | 28.84M | 29.86M | 25.7M |
| Analgesics Revenue Growth | -4.20% | -2.52% | +9.78% | -0.25% | +1.78% | -8.15% | -3.49% | +11.91% | +1.25% | -7.88% | -9.75% | +17.84% | +14.25% | -20.31% | +2.28% | -8.69% | +9.80% | +1.38% | -3.37% | +9.77% | +1.73% | -2.95% | -1.96% | +1.07% | +4.45% | -6.52% | +2.43% | +1.22% | -1.26% | -8.51% | +7.03% | -1.38% | -1.01% | -8.46% | +7.68% | +6.58% | -6.97% | -0.33% | +1.72% | +10.97% | -9.18% | +4.52% | -3.42% | +16.22% | n/a |
| Cough and Cold Revenue | 19.01M | 26.91M | 29.33M | 29.27M | 20.7M | 26.19M | 33.17M | 33.23M | 26.43M | 30.32M | 37.58M | 31.23M | 27.86M | 28.43M | 31.73M | 28.03M | 18.89M | 14.67M | 20.75M | 17.88M | 17.34M | 32.1M | 29.96M | 26.32M | 22.72M | 23.79M | 31.72M | 26.23M | 21.39M | 30.51M | 33.09M | 26.23M | 22.02M | 26.19M | 33.97M | 26.27M | 22.36M | 28.94M | 34.16M | 29.2M | 24.27M | 30.98M | 35.76M | 30.23M | 24.8M |
| Cough and Cold Revenue Growth | -29.37% | -8.25% | +0.19% | +41.45% | -20.97% | -21.06% | -0.18% | +25.76% | -12.83% | -19.33% | +20.35% | +12.07% | -2.01% | -10.37% | +13.19% | +48.36% | +28.77% | -29.29% | +16.03% | +3.13% | -45.98% | +7.14% | +13.84% | +15.83% | -4.49% | -25.00% | +20.95% | +22.64% | -29.90% | -7.81% | +26.18% | +19.08% | -15.91% | -22.90% | +29.33% | +17.47% | -22.74% | -15.28% | +16.99% | +20.35% | -21.67% | -13.37% | +18.28% | +21.90% | n/a |
| Dermatologicals Revenue | 30.11M | 29.08M | 30.66M | 35.85M | 33.35M | 30.83M | 27.77M | 34.49M | 36.02M | 31.3M | 28.2M | 33.77M | 30.46M | 27.73M | 27.37M | 33.2M | 32.09M | 24.66M | 25.39M | 28.71M | 28.32M | 24.09M | 23.88M | 28.61M | 26.43M | 24.4M | 21.98M | 25.94M | 25.65M | 22.61M | 23.3M | 26.34M | 24.63M | 20.04M | 20.43M | 23.52M | 23.37M | 20.38M | 20.26M | 23.81M | 20.63M | 19.16M | 18.23M | 18.15M | 11.56M |
| Dermatologicals Revenue Growth | +3.53% | -5.13% | -14.50% | +7.50% | +8.19% | +11.03% | -19.48% | -4.25% | +15.05% | +11.01% | -16.50% | +10.88% | +9.86% | +1.32% | -17.58% | +3.47% | +30.13% | -2.89% | -11.56% | +1.38% | +17.58% | +0.84% | -16.53% | +8.28% | +8.32% | +11.01% | -15.28% | +1.13% | +13.45% | -2.94% | -11.57% | +6.95% | +22.93% | -1.90% | -13.15% | +0.64% | +14.67% | +0.60% | -14.91% | +15.41% | +7.69% | +5.06% | +0.48% | +56.97% | n/a |
| Eye and Ear Care Revenue | 32.31M | 46.73M | 45.68M | 42.79M | 48.13M | 43.99M | 45.07M | 46.87M | 43.49M | 47.15M | 37.88M | 42.7M | 43.35M | 43.63M | 39.57M | 40.81M | 39.45M | 29.72M | 25.49M | 29.8M | 25.4M | 29.67M | 27.25M | 25.47M | 29.76M | 30.39M | 26.52M | 27.84M | 28.09M | 25.77M | 24.84M | 25.13M | 28.33M | 28.4M | 26.57M | 25.92M | 28.8M | 26.95M | 24.55M | 27.74M | 28.26M | 23.53M | 23.6M | 25.43M | 25.37M |
| Eye and Ear Care Revenue Growth | -30.86% | +2.30% | +6.76% | -11.10% | +9.41% | -2.40% | -3.84% | +7.77% | -7.76% | +24.47% | -11.27% | -1.50% | -0.65% | +10.27% | -3.03% | +3.45% | +32.74% | +16.57% | -14.47% | +17.35% | -14.39% | +8.85% | +7.00% | -14.42% | -2.06% | +14.61% | -4.76% | -0.89% | +9.03% | +3.74% | -1.15% | -11.30% | -0.26% | +6.89% | +2.49% | -10.00% | +6.89% | +9.76% | -11.51% | -1.84% | +20.13% | -0.30% | -7.22% | +0.26% | n/a |
| Gastrointestinal Revenue | 57.78M | 68.88M | 68.99M | 60.06M | 58.02M | 59.63M | 61.63M | 52.76M | 57.59M | 58.43M | 56.75M | 57.31M | 54.09M | 54.13M | 51.25M | 46.6M | 52.57M | 41.96M | 45.32M | 38.1M | 35.76M | 48.37M | 44.74M | 41.24M | 38.56M | 42.14M | 41.06M | 38.48M | 38.79M | 38.97M | 40.64M | 36.46M | 36.16M | 33.77M | 21.81M | 22.37M | 23.36M | 23.14M | 22.92M | 24.4M | 24.13M | 22.91M | 24.03M | 26.49M | 23.54M |
| Gastrointestinal Revenue Growth | -16.11% | -0.16% | +14.87% | +3.53% | -2.71% | -3.24% | +16.80% | -8.38% | -1.44% | +2.96% | -0.98% | +5.94% | -0.07% | +5.62% | +9.97% | -11.35% | +25.28% | -7.41% | +18.96% | +6.55% | -26.08% | +8.10% | +8.49% | +6.96% | -8.49% | +2.63% | +6.70% | -0.80% | -0.46% | -4.12% | +11.47% | +0.83% | +7.08% | +54.85% | -2.49% | -4.25% | +0.97% | +0.96% | -6.09% | +1.14% | +5.33% | -4.69% | -9.29% | +12.57% | n/a |
| Oral Care Revenue | 21.7M | 27.09M | 23.08M | 24.08M | 20.77M | 25.31M | 23.46M | 22.78M | 24.75M | 25.04M | 24.11M | 24.33M | 24.14M | 22.18M | 25.21M | 26.17M | 23.96M | 25.02M | 25.99M | 25.08M | 25.34M | 23.28M | 23.8M | 23.5M | 22.63M | 27.87M | 24.83M | 25.87M | 24.86M | 24.72M | 30.41M | 28.09M | 27.78M | 27.67M | 27.21M | 27.19M | 26.03M | 20.91M | 10.12M | 9.92M | 10.17M | 10.61M | 12.47M | 13.06M | 10.26M |
| Oral Care Revenue Growth | -19.90% | +17.39% | -4.16% | +15.93% | -17.93% | +7.89% | +2.99% | -7.95% | -1.17% | +3.87% | -0.91% | +0.77% | +8.83% | -12.00% | -3.68% | +9.25% | -4.23% | -3.76% | +3.65% | -1.05% | +8.88% | -2.18% | +1.25% | +3.85% | -18.79% | +12.21% | -4.00% | +4.04% | +0.58% | -18.71% | +8.27% | +1.09% | +0.41% | +1.69% | +0.09% | +4.46% | +24.48% | +106.58% | +2.02% | -2.45% | -4.10% | -14.96% | -4.51% | +27.30% | n/a |
| Other OTC Revenue | 2.93M | 3.85M | 3.48M | 3.16M | 3.3M | 3.07M | 3.11M | 2.75M | 3.1M | 2.83M | 2.9M | 2.52M | 2.85M | 2.72M | 2.75M | 2.71M | 1.81M | 1.3M | 1.5M | 1.36M | 1.26M | 1.22M | 1.29M | 1.26M | 1.29M | 1.3M | 1.59M | 1.35M | 1.24M | 1.54M | 1.63M | 1.28M | 1.25M | 1.41M | 1.39M | 1.55M | 1.49M | 1.61M | 1.56M | 1.5M | 1.42M | -134K | 1.48M | 1.93M | 2.94M |
| Other OTC Revenue Growth | -23.82% | +10.64% | +10.14% | -4.36% | +7.53% | -1.25% | +13.14% | -11.42% | +9.77% | -2.62% | +14.98% | -11.41% | +4.86% | -1.31% | +1.66% | +49.56% | +38.80% | -13.30% | +10.43% | +8.44% | +2.70% | -5.19% | +2.22% | -2.17% | -0.62% | -18.62% | +17.89% | +9.38% | -19.83% | -5.45% | +27.10% | +2.97% | -11.43% | +1.51% | -10.34% | +4.03% | -7.93% | +3.53% | +3.65% | +6.06% | -1158.96% | -109.04% | -23.05% | -34.51% | n/a |
| Women's Health Revenue | 56.76M | 63.78M | 58.13M | 60.35M | 54.58M | 60.17M | 58.27M | 62.07M | 59.91M | 63.12M | 58.06M | 64.12M | 66.05M | 63.38M | 65.57M | 68.36M | 67.19M | 70.17M | 64.49M | 65.6M | 67.84M | 64.85M | 62.12M | 62.58M | 62M | 63.61M | 64.25M | 64.88M | 65.73M | 63.26M | 66.05M | 63.34M | 66.74M | 51.68M | 31.48M | 33.9M | 33.82M | 32.75M | 34.4M | 34.41M | 33.61M | 32.04M | 31.95M | 9.78M | n/a |
| Women's Health Revenue Growth | -11.01% | +9.73% | -3.68% | +10.57% | -9.30% | +3.27% | -6.13% | +3.61% | -5.08% | +8.72% | -9.46% | -2.92% | +4.21% | -3.33% | -4.09% | +1.75% | -4.25% | +8.82% | -1.70% | -3.31% | +4.61% | +4.40% | -0.74% | +0.95% | -2.53% | -1.00% | -0.97% | -1.29% | +3.92% | -4.23% | +4.27% | -5.09% | +29.14% | +64.19% | -7.16% | +0.24% | +3.28% | -4.79% | -0.04% | +2.39% | +4.90% | +0.26% | +226.82% | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 47.36M | 46.76M | 40.07M | 42.51M | 38.65M | 41.49M | 34.13M | 30.05M | 42.84M | 37.63M | 38.35M | 31.52M | 36.16M | 36.47M | 35.59M | 30.5M |
| Non-Us Revenue Growth | +1.30% | +16.67% | -5.74% | +9.99% | -6.84% | +21.56% | +13.59% | -29.87% | +13.85% | -1.89% | +21.67% | -12.82% | -0.85% | +2.46% | +16.69% | n/a |
| United States Revenue | 219.57M | 227.72M | 236.15M | 226.67M | 199.11M | 197.3M | 203.29M | 199.35M | 208.39M | 203.92M | 199.71M | 200.63M | 204.87M | 204.94M | 203.76M | 223.48M |
| United States Revenue Growth | -3.58% | -3.57% | +4.18% | +13.84% | +0.92% | -2.95% | +1.98% | -4.34% | +2.19% | +2.11% | -0.46% | -2.07% | -0.04% | +0.58% | -8.82% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 63.39M | 64.05M | 64.13M | 67.48M | 68.28M | 63.98M | 65.47M | 66.1M | 63.92M | 58.53M | 56.96M | 70.26M | 66.67M | 64.75M | 66.22M | 72.98M | 61.91M | 60.24M | 59.48M | 58.73M | 47.68M | 63.75M | 54.87M | 61.18M | 56.51M | 55.73M | 54.99M | 61.08M | 61.05M | 157.13M | 57.04M | 60.76M | 57.28M | 70.21M | 52.81M | 47.39M | 47.09M | 46.78M | 48.07M | 44.35M | 44.01M | 43.05M |
| Selling, General, and Administrative Revenue Growth | -1.03% | -0.11% | -4.96% | -1.17% | +6.71% | -2.27% | -0.95% | +3.41% | +9.20% | +2.77% | -18.93% | +5.39% | +2.97% | -2.23% | -9.26% | +17.88% | +2.77% | +1.28% | +1.27% | +23.16% | -25.20% | +16.19% | -10.32% | +8.27% | +1.39% | +1.35% | -9.97% | +0.04% | -61.15% | +175.47% | -6.11% | +6.07% | -18.42% | +32.94% | +11.45% | +0.63% | +0.66% | -2.68% | +8.38% | +0.78% | +2.23% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue | 34.94M | 37M | 37.95M | 41.41M | 39.37M | 37.52M | 39.47M | 40.1M | 36.23M | 30.87M | 30.42M | 43.82M | 39.95M | 36.94M | 40.24M | 40.73M | 39.44M | 36.42M | 38.08M | 38.34M | 27.75M | 40.17M | 33.56M | 38.67M | 34.8M | 34.43M | 34.5M | 37.04M | 37.11M | 35.32M | 35.84M | 39.19M | 36.94M | 41.45M | 30.68M | 28.59M | 27.64M | 26.55M | 29.93M | 27.89M | 26.42M | 25.37M |
| Sales and Marketing Revenue Growth | -5.59% | -2.48% | -8.37% | +5.19% | +4.93% | -4.94% | -1.59% | +10.68% | +17.37% | +1.46% | -30.57% | +9.68% | +8.17% | -8.21% | -1.21% | +3.27% | +8.30% | -4.37% | -0.68% | +38.17% | -30.91% | +19.69% | -13.21% | +11.11% | +1.07% | -0.21% | -6.85% | -0.19% | +5.07% | -1.44% | -8.56% | +6.07% | -10.87% | +35.10% | +7.31% | +3.46% | +4.08% | -11.30% | +7.32% | +5.57% | +4.16% | n/a |